Top

Published in:

01-06-2012 | CE - LETTER TO THE EDITOR

A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score

Authors: Melina Verso, Giancarlo Agnelli, Sandro Barni, Giampietro Gasparini, Roberto LaBianca

Published in: Internal and Emergency Medicine | Issue 3/2012

Excerpt

The association between cancer and venous thromboembolism (VTE) is well established [1]. Indeed, up to 20 % of cancer patients have a symptomatic VTE, which is recognized to be one of the leading causes of death in these patients [2]. …

Agnelli G (1997) Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 78:117–120PubMed

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907PubMedCrossRef

Barni S, La Bianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179–185PubMedCrossRef

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E (2009) For the PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in outpatients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943–949PubMedCrossRef

Streiff MB, Bockenstedt PL, Cataland PR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A (2011) Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 9:714–775

Title: A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
Authors: Melina Verso
Giancarlo Agnelli
Sandro Barni
Giampietro Gasparini
Roberto LaBianca
Publication date: 01-06-2012
Publisher: Springer Milan
Published in: Internal and Emergency Medicine / Issue 3/2012
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-012-0784-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2012

Optimized search strategy for detecting scientifically strong studies on treatment through PubMed

Platelets, oxidative stress and preservation of the vascular endothelium: is it a matter of fat?

Aging reduces complexity of heart rate variability assessed by conditional entropy and symbolic analysis

Is magnetic resonance safe in implanted cardiac devices patients?

The FOUR score: is it just another new coma scale?

Structural abnormalities of small resistance arteries in essential hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page